RxDoctor Payments Data

Michael Atkins, MD

Internal Medicine · Crisfield, MDNPI 1881651172

Payments from drug & device makers

$425in general payments, 2019–2025

Across 18 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$148
  • Indivior Inc.$121
  • Pfizer$64
  • AstraZeneca$31
  • Novo Nordisk$19
  • Kowa Pharmaceuticals America, Inc.$17
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$41297%
  • Education$133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$425 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$68,590
Medicare patients
217
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$83,197
RybelsusSemaglutide37$50,794
FarxigaDapagliflozin Propanediol42$47,778
EntrestoSacubitril/Valsartan34$29,569
XareltoRivaroxaban35$27,776
JanuviaSitagliptin Phosphate25$23,294
JardianceEmpagliflozin16$22,586
Breo ElliptaFluticasone/Vilanterol21$9,054
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$8,956
Varenicline Tartrate21$7,643
VascepaIcosapent Ethyl15$7,487
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl52$6,995
Atorvastatin Calcium391$3,731
Pravastatin Sodium175$3,230
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$83,197121 claims
Novo NordiskRybelsus$19$50,79437 claims
AstraZenecaFarxiga$31$47,77842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Crisfield

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →